SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Valence8 US LP

CIK 0001943819 · ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142 · 617-233-0428

Reported Value
$208M
Q4 2024
Positions
10
Filings on Record
14
2019–present window
Filed
Feb 12, 2025
original filing

Summary

Valence8 US LP reported $208M in U.S.-listed holdings across 10 positions for Q4 2024.

The portfolio is heavily concentrated: Ishares Tr alone accounts for 28.0% of reported value.

Compared with Q3 2024, the fund opened 1 new position and exited 47.

Portfolio Metrics

Turnover
+3.5%
vs prior filed quarter
Top-10 Concentration
+100.0%
share of reported value
Largest Position
+28.0%
Ishares Tr
New / Exited
1 / 47
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $132MQ4 ’22Q1 ’23: $170MQ2 ’23: $152MQ2 ’23Q3 ’23: $158MQ4 ’23: $171MQ4 ’23Q1 ’24: $192MQ2 ’24: $192MQ2 ’24Q3 ’24: $241MQ4 ’24: $208MQ4 ’24Q1 ’25: $213MQ2 ’25: $238MQ2 ’25Q3 ’25: $292MQ4 ’25: $337MQ4 ’25Q1 ’26: $286Mfilingsflow.com

Portfolio Composition

By security type
ETP: 100.0%
  • ETP · 100.0% · $208M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ISHARES TRNEW+77.9K77.9K+$8M$8M
AZNNASTRAZENECA PLCSOLD OUT−64.0K0−$5M$0
AMGNAMGEN INCSOLD OUT−4.0K0−$1M$0
SLNOEURSOLENO THERAPEUTICS INCSOLD OUT−22.2K0−$1M$0
IM8NINSMED INCSOLD OUT−14.5K0−$1M$0
JAZZ PHARMACEUTICALS PLCSOLD OUT−9.0K0−$999,236$0
BMYBRISTOL-MYERS SQUIBB COSOLD OUT−17.8K0−$920,196$0
ASCENDIS PHARMA A/SSOLD OUT−4.6K0−$684,586$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

5 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ISHARES TRMSCI USA QLT FCT · MSCI INTL QUALTY · EAFE VALUE ETF · EXPANDED TECH · MSCI UK ETF NEW61.45%$128M1.92M
2NDQINVESCO QQQ TRhistory →UNIT SER 120.57%$43M83.8K
3XLUSELECT SECTOR SPDR TRSBI CONS STPLS · SBI INT-UTILS8.17%$17M218.4K
4VTVVANGUARD INDEX FDShistory →VALUE ETF7.92%$16M97.4K
5ISHARES INCMSCI JPN ETF NEW1.89%$4M58.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$286M14May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$337M15Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$292M14Nov 7, 202513F-HRchanges · EDGAR ↗
Q2 2025$238M12Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$213M10May 12, 202513F-HRchanges · EDGAR ↗
Q4 2024$208M10Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$241M62Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$192M9Aug 6, 202413F-HRchanges · EDGAR ↗
Q1 2024$192M9May 6, 202413F-HRchanges · EDGAR ↗
Q4 2023$171M9Feb 1, 202413F-HRchanges · EDGAR ↗
Q3 2023$158M13Nov 9, 202313F-HRchanges · EDGAR ↗
Q2 2023$152M13Aug 1, 202313F-HRchanges · EDGAR ↗
Q1 2023$170M14May 9, 202313F-HRchanges · EDGAR ↗
Q4 2022$132M12Jan 31, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.